Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOCTP.L Regulatory News (OCTP)

  • There is currently no data for OCTP

Total Voting Rights

28 May 2021 07:00

RNS Number : 8646Z
Oxford Cannabinoid Tech.Holdings
28 May 2021
 

Oxford Cannabinoid Technologies Holdings Plc 

 

Total Voting Rights

 

 

Oxford Cannabinoid Technologies Holdings Plc ("Company"), announces that, in accordance with FCA's Disclosure Guidance and Transparency Rules, as at 28 May 2021, the Company's issued share capital consists of 960,415,644 Ordinary Shares of £0.01, each with one voting right. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 960,415,644.

 

The above figure of 960,415,644 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

For more information:

 

The Company

Oxford Cannabinoid Technologies Holdings Plc

Dr John Lucas

+44 (0)7956 873125

 

The Financial Adviser

Cairn Financial Advisers LLP

Emily Staples or Jo Turner

+44 (0)20 7213 0897

or +44 (0)20 7213 0885

The Corporate Adviser

States Bridge Capital Ltd

Damion Carruel

+44 (0)7775516745

The PR Adviser

Acuitas Communications

Simon Nayyar or James Gittings

44 (0)20 3848 2815 or

+44 (0)20 3848 2812

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRPPUACAUPGUMQ
Date   Source Headline
4th Mar 20221:00 pmRNSRequisition of General Meeting - Update
3rd Mar 20224:41 pmRNSSecond Price Monitoring Extn
3rd Mar 20224:36 pmRNSPrice Monitoring Extension
22nd Feb 20227:00 amRNSInterim Results: 6 months to 30 November 2021
18th Feb 20225:15 pmRNSRequisition of General Meeting
7th Feb 20227:00 amRNSNotice of Interim Results & Investor Presentations
31st Jan 20227:00 amRNSBoard Changes
24th Jan 20224:36 pmRNSPrice Monitoring Extension
18th Jan 20227:00 amRNSTrading Update & Change of Accounting Year-End
7th Jan 20224:40 pmRNSSecond Price Monitoring Extn
7th Jan 20224:35 pmRNSPrice Monitoring Extension
15th Dec 20212:06 pmRNSSecond Price Monitoring Extn
15th Dec 20212:00 pmRNSPrice Monitoring Extension
2nd Dec 20212:11 pmRNSHolding in Company
2nd Dec 20212:09 pmRNSHolding in Company
2nd Dec 20217:00 amRNSDirector Dealings
1st Dec 20217:00 amRNSAdmission to Trading on the US OTC QB Market
30th Nov 20215:00 pmRNSCorporate Adviser Change
29th Nov 20214:41 pmRNSSecond Price Monitoring Extn
29th Nov 20214:36 pmRNSPrice Monitoring Extension
24th Nov 20215:06 pmRNSDirectorate Change
24th Nov 20213:35 pmRNSResult of AGM
23rd Nov 20217:00 amRNSNew Agreement with Dalriada Drug Discovery Inc.
17th Nov 20217:00 amRNSNew Agreement signed with Oxford Stemtech Limited
11th Nov 20217:00 amRNSDirector Dealing Update
5th Nov 20211:35 pmRNSDirector Dealing Update & Board Changes
1st Nov 20217:00 amRNSDirector Dealing
27th Oct 20217:00 amRNSPosting of Annual Report & Notice of AGM
26th Oct 20217:00 amRNSAppointment of North American IR Adviser
13th Oct 20217:00 amRNS2021 Final Results and Notice of AGM
11th Oct 20217:00 amRNSNew Partnerships Targeting Trigeminal Neuralgia
23rd Sep 20214:21 pmRNSRescheduling of Final Results Announcement
22nd Sep 20217:00 amRNSExclusive Agreement with Canopy Growth Corporation
23rd Aug 20217:00 amRNSPre-Close Trading Update & Notice of Final Results
28th Jul 20217:00 amRNSPost IPO Review & Notice of Trading Update
25th Jun 20218:14 amRNSHolding(s) in Company
4th Jun 20213:33 pmRNSHolding(s) in Company
4th Jun 20213:20 pmRNSHolding(s) in Company
4th Jun 20217:00 amRNSCompany Presentation Webinar to Retail Investors
1st Jun 20217:00 amRNSConsultancy Agreement with Voisin Consulting SARL
28th May 20217:00 amRNSTotal Voting Rights
25th May 202110:13 amRNSHolding(s) in Company
25th May 20219:05 amRNSHolding(s) in Company
24th May 20215:32 pmRNSHolding(s) in Company
21st May 20217:00 amRNSAdmission to Trading and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.